April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
February 2024 in “Indian Journal of Chemistry” Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
April 2017 in “Journal of Investigative Dermatology” Fisetin may help treat psoriasis and reduce skin inflammation.
June 2025 in “Veterinary Sciences” Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.
2 citations
,
February 2021 in “Indian Dermatology Online Journal” Imatinib can cause hair loss due to lichen planopilaris.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
March 2023 in “International Journal of Trichology” A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
9 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
2 citations
,
January 2004 in “Linchuang pifuke zazhi” ZD1839 can cause skin issues like acne and hair changes.
More research is needed to understand chemotherapy-induced hair loss and its phases.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
475 citations
,
October 2006 in “Proceedings of the National Academy of Sciences” Folliculin helps regulate energy and nutrient sensing, impacting Birt–Hogg–Dubé syndrome.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
7 citations
,
July 2019 in “The Journal of Dermatology” Terbinafine effectively treated kerion celsi despite disrupted immune responses.
5 citations
,
July 2024 in “Archives of Dermatological Research”
40 citations
,
January 2017 in “Intestinal Research” Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.